Standout Papers
- Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL (2006)
- The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 (1998)
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer (2004)
Immediate Impact
20 by Nobel laureates 13 from Science/Nature 97 standout
Citing Papers
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
2021 Standout
Works of Leila Alland being referenced
Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
2004 Standout
Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer
2004
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Leila Alland | 2060 | 938 | 1236 | 2094 | 39 | 4.9k | |
| Nadia Carlesso | 969 | 719 | 1331 | 2722 | 65 | 5.4k | |
| Siddhartha Jaiswal | 1335 | 1485 | 2670 | 2058 | 52 | 6.7k | |
| Brunhilde Felding‐Habermann | 1939 | 414 | 780 | 2366 | 43 | 5.4k | |
| Erkki Koivunen | 2081 | 291 | 626 | 3768 | 71 | 6.6k | |
| Achim Krüger | 2101 | 333 | 471 | 2555 | 107 | 5.7k | |
| Joel A. Spencer | 1858 | 1032 | 735 | 1865 | 42 | 5.3k | |
| Judith A. Varner | 2767 | 374 | 595 | 4690 | 78 | 9.0k | |
| Randall H. Kramer | 1259 | 230 | 528 | 3480 | 101 | 7.1k | |
| Rafael Fridman | 1749 | 233 | 743 | 2517 | 52 | 5.5k | |
| Mark P. Chao | 2537 | 613 | 1531 | 2626 | 70 | 8.3k |
All Works
Loading papers...